FibroGen Inc (FGEN)
1.135
-0.02
(-2.16%)
USD |
NASDAQ |
Jun 14, 15:16
FibroGen Free Cash Flow (Quarterly): -59.32M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -59.32M |
December 31, 2023 | -18.57M |
September 30, 2023 | -85.22M |
June 30, 2023 | -111.56M |
March 31, 2023 | -102.18M |
December 31, 2022 | -52.85M |
September 30, 2022 | -52.74M |
June 30, 2022 | -33.97M |
March 31, 2022 | -45.11M |
December 31, 2021 | -56.36M |
September 30, 2021 | 17.68M |
June 30, 2021 | -28.24M |
March 31, 2021 | -45.50M |
December 31, 2020 | -9.618M |
September 30, 2020 | -1.768M |
June 30, 2020 | 148.94M |
March 31, 2020 | -59.94M |
December 31, 2019 | -46.80M |
September 30, 2019 | -29.29M |
June 30, 2019 | -30.38M |
March 31, 2019 | 22.00M |
Date | Value |
---|---|
December 31, 2018 | -20.63M |
September 30, 2018 | 7.101M |
June 30, 2018 | -36.83M |
March 31, 2018 | -33.80M |
December 31, 2017 | -4.694M |
September 30, 2017 | -21.81M |
June 30, 2017 | -20.73M |
March 31, 2017 | -27.77M |
December 31, 2016 | -18.69M |
September 30, 2016 | -1.854M |
June 30, 2016 | 44.56M |
March 31, 2016 | -18.16M |
December 31, 2015 | -39.61M |
September 30, 2015 | -38.80M |
June 30, 2015 | 100.51M |
March 31, 2015 | -42.64M |
December 31, 2014 | -26.34M |
September 30, 2014 | -32.65M |
June 30, 2014 | 91.14M |
March 31, 2014 | -17.85M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-111.56M
Minimum
Jun 2023
148.94M
Maximum
Jun 2020
-35.14M
Average
-45.31M
Median
Free Cash Flow (Quarterly) Benchmarks
Regeneron Pharmaceuticals Inc | 1.351B |
Annovis Bio Inc | -7.033M |
Emergent BioSolutions Inc | -73.40M |
Vertex Pharmaceuticals Inc | 1.058B |
Nanoviricides Inc | -1.988M |